SCHEMBL23934267

SCHEMBL23934267

CN1C(=O)c2c(NC(=O)c3ccc(Cl)s3)ccc(NC(=O)c3ccc(Cl)s3)c2C1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.53
ALDH1A1 P00352 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
KMT2A Q03164 8/20 0.51
NPC1 O15118 8/20 0.51
RAB9A P51151 8/20 0.51
MEN1 O00255 5/20 0.51
KDM4E B2RXH2 6/20 0.50
TSHR P16473 1/20 0.50
LMNA P02545 3/20 0.48
MAPK1 P28482 3/20 0.48
MAPT P10636 2/20 0.45
PRSS12 P56730 1/20 0.44
NFKB1 P19838 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44
NPSR1 Q6W5P4 3/20 0.44
TP53 P04637 2/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23934204 0.82 KDM4E (0.54) HPGDALDH1A1SMN1; SMN2KMT2ANPC1
SCHEMBL23934282 0.79 KDM4E (0.59) HPGDALDH1A1SMN1; SMN2KMT2ANPC1
SCHEMBL23934287 0.77 KDM4E (0.54) HPGDALDH1A1SMN1; SMN2KMT2ANPC1
SCHEMBL4314316 0.71 ACHE (0.45) HPGDALDH1A1SMN1; SMN2KMT2ANPC1
SCHEMBL13950025 0.71 ALDH1A1 (0.47) HPGDALDH1A1SMN1; SMN2KMT2ANPC1
SCHEMBL3380643 0.71 HPGD (0.53) HPGDALDH1A1SMN1; SMN2KMT2ANPC1
SCHEMBL23934205 0.71 POLB (0.53) HPGDALDH1A1SMN1; SMN2KMT2ANPC1
SCHEMBL4633508 0.71 KDM4E (0.67) HPGDALDH1A1SMN1; SMN2KMT2ANPC1
SCHEMBL4303219 0.71 HPGD (0.46) HPGDALDH1A1SMN1; SMN2KMT2ANPC1
SCHEMBL3379082 0.70 KDM4E (0.58) HPGDALDH1A1SMN1; SMN2KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS XAVIER UNIVERSITY OF LOUISIANA 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS RPS6KA6, RPS6KA1, RPS6KA3 HPGD 4094/4885ALDH1A1 4396/4885SMN1; SMN2 3184/4885
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics RPS6KA6, RPS6KA1, RPS6KA3 HPGD 4094/4885ALDH1A1 4396/4885SMN1; SMN2 3184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.